Mobile

A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/form...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-001337-34

A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 μg, compared with salmeterol/fluticasone (Seretide® Diskus®) 50/500 μg, both given as one inhalation twice daily for one week each

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate early morning efficacy of Symbicort Turbuhaler 320/9 µg one inhalation twice daily compared to Seretide Diskus 50/500 µg one inhalation twice daily in patients with severe COPD over one week treatment.

Critère d'inclusion

  • Severe Chronic Obstructive Pulmonary Disease (COPD)

Liens